ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

apalutamide

Also written as “Apalutamide”, “JNJ-56021927” and “ARN-509”.

Its studies are mostly in Prostatic Neoplasms · Prostatic Neoplasms, Castration-Resistant · Salivary Gland Neoplasms, led by 2 companies.

Drug pageApalutamide: every studyAll 85 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Sep 26, 201928 company-led studies, 11 open or runningNext primary completion: Dec 1, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Johnson & Johnson2711 open or runningphase 4since Sep 26, 2019Jul 27, 2010Dec 1, 2026phase 3 · NCT03767244
Sumitomo Pharmaits history only10 open or runningphase 1since Dec 7, 2020Dec 7, 2020none ahead

Also a collaborator on its studies: Bayer.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Johnson & Johnson only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

Not listed one by one: 12 earlier studies, Jul 27, 2010 to Jul 1, 2015.

  1. Jun 9, 2015Named apalutamideINNProposed as its International Nonproprietary Name in WHO's List 113 · before, JNJ-56021927, ARN-509, JNJ 56021927
  2. Aug 13, 2015Phase 1 study in Hepatic ImpairmentNCT02524717 · 24 enrolled · United States
  3. Aug 21, 2015Phase 3 study in Prostatic NeoplasmsNCT02531516 · 1,503 enrolled · United States, Argentina, Belgium and more
  4. Oct 15, 20152 phase 1 studiesNCT02578797, NCT02592317
  5. Jun 29, 2016Phase 1 study in HealthyNCT02835508 · 18 enrolled · Japan
  6. Sep 15, 2016Phase 2 study in Prostatic Neoplasms, Castration-ResistantNCT02906605 · United States
  7. Oct 4, 2016Phase 1 study in Prostatic NeoplasmsNCT02924766 · 34 enrolled · United States, Canada
  8. May 2, 2018Phase 1 study in Prostatic NeoplasmsNCT03523442 · 19 enrolled · China
  9. Dec 5, 2018Phase 3 study in Prostatic NeoplasmsNCT03767244 · 2,517 enrolled · United States, Argentina, Australia and more
  10. Jan 11, 2019Phase 1 study in HealthyNCT03802682 · 12 enrolled · Belgium
  11. Sep 26, 2019Phase 4 study in Prostatic NeoplasmsNCT04108208 · 75 enrolled · China
  12. Nov 5, 2019Phase 1 study in Hepatic ImpairmentNCT04154774 · 18 enrolled · United States
  13. Mar 26, 2020Phase 2 study in Salivary Gland NeoplasmsNCT04325828 · 31 enrolled · Japan
  14. Sep 17, 2020Phase 3 study in Prostatic NeoplasmsNCT04557059 · 691 enrolled · United States, Australia, Austria and more
  15. May 23, 2023Phase 3 study in Metastatic Castrate-sensitive Prostate CancerNCT05884398 · 420 enrolled · United States, Australia, Brazil and more

Ahead

  1. Dec 1, 2026Primary completion: phase 3 study in Prostatic NeoplasmsNCT03767244
  2. Mar 1, 2027Primary completion: phase 3 study in Prostatic NeoplasmsNCT02531516
  3. Aug 27, 2029Primary completion: phase 3 study in Prostatic NeoplasmsNCT04557059

TargetBeta

AR →read by rule
“A small molecule and androgen receptor (AR) antagonist ”NCIt, by rule
“Androgen Receptor antagonist”ChEMBL 37, by rule

Other programs on AR

ProgramCompanyFurthest phaseStudies
enzalutamideruleAstellas Pharmaphase 469
darolutamideruleBayerphase 426
Clascoteronerulecassiopea-spaphase 419
ostarinerulegtxphase 315
rezvilutamideruleJiangsu HengRui Medicinephase 313
dezandrodegruleBristol-Myers Squibbphase 35
Cyproterone AcetateruleEurofarma Laboratoriosphase 34
Androgen Receptor-targeting Regulated Induced Proximity Targeting Chimera HLD-0915Johnson & Johnsonphase 33
HRS-5041Jiangsu HengRui Medicinephase 26
luxdegalutamideNovartisphase 23
luxdegalutamideNovartisphase 22
Androgen Receptor Degrader AZD9750ruleAstraZenecaphase 21

Studies

All 27 Johnson & Johnson leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05884398Metastatic Castrate-sensitive Prostate Cancer · United States, Australia, Brazil and more3Active, not recruitingOct 12, 2026420
NCT04557059Prostatic Neoplasms · United States, Australia, Austria and more3Active, not recruitingAug 27, 2029691
NCT04325828Salivary Gland Neoplasms · Japan2Active, not recruitingJun 9, 202131
NCT04154774Hepatic Impairment · United States1CompletedFeb 10, 202518
NCT04108208Prostatic Neoplasms · China4CompletedJun 1, 202375
NCT03802682Healthy · Belgium1CompletedApr 11, 201912
NCT03767244Prostatic Neoplasms · United States, Argentina, Australia and more3Active, not recruitingDec 1, 20262,517
NCT03523442Prostatic Neoplasms · China1Active, not recruitingJul 9, 201919
NCT02924766Prostatic Neoplasms · United States, Canada1CompletedJul 18, 201934
NCT02906605Prostatic Neoplasms, Castration-Resistant · United States2WithdrawnSep 20180
NCT02835508Healthy · Japan1CompletedDec 201618
NCT02592317Prostatic Neoplasms, Castration-Resistant · Moldova, Spain1Active, not recruitingNov 7, 201623
NCT02578797Prostatic Neoplasms · United States, Canada, Moldova, Republic of and more1CompletedSep 20, 201645
NCT02531516Prostatic Neoplasms · United States, Argentina, Belgium and more3Active, not recruitingMar 1, 20271,503
NCT02524717Hepatic Impairment · United States1CompletedFeb 9, 201724
NCT02489318Prostatic Neoplasms · United States, Argentina, Australia and more3Active, not recruitingSep 7, 20201,052
NCT02257736Prostatic Neoplasms · United States, Argentina, Australia and more3Active, not recruitingMar 19, 2018982
NCT02230033Healthy · United States1CompletedDec 201445
NCT02162836Prostatic Neoplasms, Castration-Resistant · Japan1CompletedMay 27, 20196
NCT02160756Healthy1CompletedNov 201475
NCT02123758Prostatic Neoplasms · United States, Canada, Netherlands and more1Active, not recruitingJun 27, 201657
NCT02031666Healthy · United States1CompletedApr 2014120
NCT01946204Prostatic Neoplasms · United States, Australia, Austria and more3Active, not recruitingMay 19, 20171,207
NCT01822041Healthy · Netherlands1CompletedJun 201312
NCT01792687Prostatic Neoplasms · United States1CompletedMay 10, 20146
NCT01790126Prostatic Neoplasms · United States2CompletedMar 1, 201990
NCT01171898Prostatic Neoplasms · United States2CompletedAug 20, 2012127

How it is read

Names in the registry

  • “Apalutamide”, 18 entries
  • “JNJ-56021927”, 4 entries
  • “ARN-509”, 3 entries
  • “JNJ 56021927”, 1 entry
  • “apalutamide”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.